Evaxion Biotech launches an enhanced version of its clinically validated AI-Immunology platform with an update of its EDEN AI prediction model. Among other improvements, the model can now predict toxin antigens, allowing for the development of improved bacterial vaccines. “Today’s launch of the improved EDEN AI prediction model marks an important milestone for Evaxion, further strengthening our AI-Immunology platform. As one of the few truly AI-first TechBio companies, our AI-Immunology platform is at the forefront of innovation. We will continue to invest in its development and refinement to further improve our ability to discover novel targets and develop advanced vaccines,” says Christian Kanstrup, CEO of Evaxion.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
- Evaxion’s AI-Designed Cancer Vaccine Shows Promise
- Evaxion Biotech announces one-year data from Phase 2 trial with EVX-01
- Evaxion’s Breakthrough in Gonorrhea Vaccine Development
- Evaxion’s EVX-01 Shows Promise in Melanoma Trial
